류 30 · Pharmaceutical products
3004.90.94
Containing cimetidine (INN) or ranitidine (INN) other than for injection
- 3004 Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale
- 3004.90 - Other:
- - - Other:
- - - - Containing cimetidine (INN) or ranitidine (INN) other than for injection
Thuốc (trừ các mặt hàng thuộc nhóm 30.02, 30.05 hoặc 30.06) gồm các sản phẩm đã hoặc chưa pha trộn dùng cho phòng bệnh hoặc chữa bệnh, đã được đóng gói theo liều lượng (kể cả các sản phẩm thuộc loại dùng để hấp thụ qua da) hoặc làm thành dạng nhất định hoặc đóng gói để bán lẻ / - Loại khác: / - - Loại khác: / - - - Chứa cimetidine (INN) hoặc ranitidine (INN) trừ dạng tiêm
2026년 적용 세금
출처: 통합 세율표 BT2026(2026년 4월 5일 갱신)특별 특혜(FTA) 세율 – 2026년
| FTA | 세율 | 데이터 근거 | 원산지 증명 | 법적 근거 | 상태 |
|---|---|---|---|---|---|
| ACFTA | 0% 공표 최저 세율 | BT2026 통합 세율표 2022 - 2027 (một mức cho cả giai đoạn) |
E | 118/2022/NĐ-CP | 종가세 |
| AHKFTA | 0% 공표 최저 세율 | BT2026 통합 세율표 2026 |
AHK | 123/2022/NĐ-CP | 종가세 |
| AJCEP | 0% 공표 최저 세율 | BT2026 통합 세율표 01/4/2026 - 31/3/2027 |
AJ | 120/2022/NĐ-CP | 종가세 |
| AKFTA | 0% (제외 LA, MY) 공표 최저 세율 | BT2026 통합 세율표 2022 - 2027 (một mức cho cả giai đoạn) |
AK | 119/2022/NĐ-CP | 종가세 |
| ATIGA | 0% 공표 최저 세율 | BT2026 통합 세율표 2026 |
D | 126/2022/NĐ-CP | 종가세 |
| CPTPP | 0% 공표 최저 세율 | BT2026 통합 세율표 (VI) |
CPTPP | 115/2022/NĐ-CP | 종가세 |
| VJEPA | 0% 공표 최저 세율 | BT2026 통합 세율표 01/4/2026 - 31/3/2027 |
JV · Form VJ | 124/2022/NĐ-CP | 종가세 |
| VKFTA | 0% 공표 최저 세율 | BT2026 통합 세율표 2026 |
VK | 125/2022/NĐ-CP | 종가세 |
| VN-EAEU | 0% 공표 최저 세율 | BT2026 통합 세율표 2026 |
EAV | 113/2022/NĐ-CP | 종가세 |
| VN-LAO | 0% 공표 최저 세율 | BT2026 통합 세율표 | S | 206/2025/NĐ-CP | 종가세 |
| VIFTA | 0% 공표 최저 세율 | BT2026 통합 세율표 2026 |
Form VI (verify) | 131/2024/NĐ-CP | 종가세 |
| EVFTA | 0.6% | BT2026 통합 세율표 2026 |
EUR.1 | 116/2022/NĐ-CP | 종가세 |
| UKVFTA | 0.6% | BT2026 통합 세율표 2026 |
EUR.1 | 117/2022/NĐ-CP | 종가세 |
| VCFTA | 1% | BT2026 통합 세율표 2026 |
VC | 112/2022/NĐ-CP | 종가세 |
| RCEP (부속서 A) BN, KH, ID, LA, MY, MM, PH, SG, TH |
2.5% | BT2026 통합 세율표 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | 종가세 |
| RCEP (부속서 B) AU |
2.5% | BT2026 통합 세율표 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | 종가세 |
| RCEP (부속서 C) CN |
2.5% | BT2026 통합 세율표 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | 종가세 |
| RCEP (부속서 E) KR |
2.5% | BT2026 통합 세율표 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | 종가세 |
| RCEP (부속서 F) NZ |
2.5% | BT2026 통합 세율표 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | 종가세 |
| RCEP (부속서 D) JP |
2.7% | BT2026 통합 세율표 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | 종가세 |
| AANZFTA | 5% | BT2026 통합 세율표 2022 - 2027 (một mức cho cả giai đoạn) |
AANZ | 121/2022/NĐ-CP | 종가세 |
| AIFTA | 5% | BT2026 통합 세율표 01/01/2026 - 31/12/2026 |
AI | 122/2022/NĐ-CP | 종가세 |
| VN-CAM | 데이터 없음 | 데이터 없음 | S | 56/2026/NĐ-CP | 데이터 없음 |
| VNCU | 데이터 없음 | 데이터 없음 | VNCB · Form VC (Cuba) | 114/2022/NĐ-CP | 데이터 없음 |
세율이 공표되었다고 해서 물품이 자격을 갖춘 것은 아닙니다. 원산지 규정 충족과 유효한 원산지 증명이 필요합니다.
세율 이력 / 연도별 인하
2022~2027년 FTA 양허표 워크시트에서
| FTA | 기간 |
|---|---|
| ACFTA AC · 행 4575 |
2022 - 2027 (một mức cho cả giai đoạn)0%
|
| ATIGA AT · 행 4536 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| AJCEP AJ · 행 4574 |
30/12/2022 - 31/3/20230%
01/4/2023 - 31/3/20240%
01/4/2024 - 31/3/20250%
01/4/2025 - 31/3/20260%
01/4/2026 - 31/3/20270%
01/4/2027 - 31/3/20280%
|
| VJEPA VJ · 행 4578 |
30/12/2022 - 31/3/20230%
01/4/2023 - 31/3/20240%
01/4/2024 - 31/3/20250%
01/4/2025 - 31/3/20260%
01/4/2026 - 31/3/20270%
01/4/2027 - 31/3/20280%
|
| AKFTA AK · 행 4578 |
2022 - 2027 (một mức cho cả giai đoạn)0%
제외 국가: LA, MY 제외가 있는 세율: 0(-LA, MY) |
| AANZFTA AANZ · 행 4542 |
2022 - 2027 (một mức cho cả giai đoạn)5%
세율 열 F(숨김): 5 |
| AIFTA AI · 행 4538 |
30/12/20225%
31/12/2022 - 30/12/20235%
31/12/2023 - 30/12/20245%
31/12/2024 - 31/12/20255%
01/01/2026 - 31/12/20265%
01/01/2027 - 31/12/20275%
|
| VKFTA VK · 행 4538 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| VCFTA VC · 행 4585 |
20223%
20232%
20242%
20251%
20261%
20270%
|
| VN-EAEU EAV · 행 4582 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| AHKFTA AKH · 행 4590 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| EVFTA EV-NK · 행 4561 |
20223.1%
20232.5%
20241.8%
20251.2%
20260.6%
20270%
변경 표시(보조): X |
| UKVFTA UKV · 행 4563 |
20223.1%
20232.5%
20241.8%
20251.2%
20260.6%
20270%
변경 표시(보조): X |
| CPTPP CPTPP · 행 4561 |
(I) → 2021*0%
(II) → 2022*0%
(III) → 2023*0%
(IV) → 2024*0%
(V) → 2025*0%
(VI) → 2026*0%
(VII) → 2027*0%
|
| RCEP A RCEPT-A · 행 4582 |
20224.5%
20234%
20243.5%
20253%
20262.5%
20272%
|
| RCEP B B · 행 4582 |
20224.5%
20234%
20243.5%
20253%
20262.5%
20272%
|
| RCEP C C · 행 4582 |
20224.5%
20234%
20243.5%
20253%
20262.5%
20272%
|
| RCEP D D · 행 4582 |
20224.5%
20234.1%
20243.6%
20253.2%
20262.7%
20272.3%
|
| RCEP E E · 행 4585 |
20224.5%
20234%
20243.5%
20253%
20262.5%
20272%
|
| RCEP F F · 행 4582 |
20224.5%
20234%
20243.5%
20253%
20262.5%
20272%
|
| VIFTA VI · 행 4224 |
20240%
20250%
20260%
20270%
보조 열 J: 8 |
* CPTPP 기간 (I)~(VII)은 BT2026과 대조하여 연도에 매핑했습니다(파생 데이터 – 확인 필요).
자문 및 경고
일반 평가(원산지는 고려하지 않음). 원산지별 평가는 스마트 관세 자문을 실행하세요.
YELLOW – REVIEW REQUIRED DOC-004 Other item policy
- 설명
- Item policy (source, Vietnamese): Thuốc chỉ chứa 01 thành phần dược chất XK, NK (09/2024/TT-BYT-DM8)
- 법적 근거
- 09/2024/TT-BYT-DM
- 권장 조치
- Read the referenced instruments.
- 확인 상태
- 원본에 인용된 문서이며 효력은 확인되지 않음
YELLOW – REVIEW REQUIRED FTA-013 FTA rate not lower than MFN
- 설명
- AANZFTA 5%, AIFTA 5%: the preferential rate is equal to or higher than the MFN rate (5%) in the source tariff – claiming the FTA brings no saving.
- 관련 데이터
- MFN 5%
- 권장 조치
- Consider the MFN rate (if the origin qualifies for MFN treatment) instead of preparing FTA origin documents.
- 확인 상태
- 미확인 – 확인 필요
YELLOW – REVIEW REQUIRED HS-003 Classification Review Required – similar lines exist
- 설명
- Subheading 3004.90 has 28 lines; 3004.90.94 is distinguished from its siblings by: Containing cimetidine (INN) or ranitidine (INN) other than for injection.
- 관련 데이터
- 3004.90.10 Transdermal therapeutic system patches for the treatment of cancer or heart diseases; 3004.90.20 Closed sterile water for inhalation, pharmaceutical grade; 3004.90.30 Antiseptics; 3004.90.41 Containing procaine hydrochloride; 3004.90.49 Other; 3004.90.51 Containing acetylsalicylic acid, paracetamol or dipyrone (INN), of a kind taken orally
- 법적 근거
- 31/2022/TT-BTC
- 권장 조치
- Verify the distinguishing features; consider an advance classification ruling if uncertain.
- 확인 상태
- 미확인 – 확인 필요
YELLOW – REVIEW REQUIRED TAX-001 Several VAT rates
- 설명
- The VAT column shows "5/8/10".
- 법적 근거
- 181/2025/NĐ-CP
- 권장 조치
- Determine the VAT rate by the nature of goods and reduction rules (174/2025/NĐ-CP, Annex I/II).
- 확인 상태
- 미확인 – 확인 필요
GRAY – DATA UNAVAILABLE TR-004 Not Assessed – Additional Regulatory Verification Required
- 설명
- The source file records no trade remedy for 3004.90.94. This does NOT mean there is no risk.
- 권장 조치
- Check the MOIT Trade Remedies Authority database.
- 확인 상태
- 미확인 – 확인 필요
GREEN – VERIFIED DQ-001 MFN rate present in the source
- 설명
- The MFN rate 5% for 3004.90.94 was checked against BT2026 (cell BT2026!N4653), basis 26/2023/NĐ-CP.
- 법적 근거
- 26/2023/NĐ-CP
- 권장 조치
- Verification scope: matched against source file version 2026.04.05; not a substitute for the legal text.
- 확인 상태
- 원본 세율 파일과 대조 완료
류의 주
Notes
1. This Chapter does not cover:
(a) Foods or beverages (such as dietetic, diabetic or fortified foods, food supplements, tonic beverages and mineral waters), other than nutritional preparations for intravenous administration (Section IV);
(b) Products, such as tablets, chewing gum or patches (transdermal systems), containing nicotine and intended to assist tobacco use cessation (heading 24.04);
(c) Plasters specially calcined or finely ground for use in dentistry (heading 25.20);
(d) Aqueous distillates or aqueous solutions of essential oils, suitable for medicinal uses (heading 33.01);
(e) Preparations of headings 33.03 to 33.07, even if they have therapeutic or prophylactic properties;
(f) Soap or other products of heading 34.01 containing added medicaments;
(g) Preparations with a basis of plaster for use in dentistry (heading 34.07);
(h) Blood albumin not prepared for therapeutic or prophylactic uses (heading 35.02); or
(ij) Diagnostic reagents of heading 38.22.
2. For the purposes of heading 30.02, the expression “immunological products” applies to peptides and proteins (other than goods of heading 29.37) which are directly involved in the regulation of immunological processes, such as monoclonal antibodies (MAB), antibody fragments, antibody conjugates and antibody fragment conjugates, interleukins, interferons (IFN), chemokines and certain tumor necrosis factors (TNF), growth factors (GF), hematopoietins and colony stimulating factors (CSF).
3. For the purposes of headings 30.03 and 30.04 and of Note 4 (d) to this Chapter, the following are to be treated:
(a) As unmixed products:
(1) Unmixed products dissolved in water;
(2) All goods of Chapter 28 or 29; and
(3) Simple vegetable extracts of heading 13.02, merely standardised or dissolved in any solvent;
(b) As products which have been mixed:
(1) Colloidal solutions and suspensions (other than colloidal sulphur);
(2) Vegetable extracts obtained by the treatment of mixtures of vegetable materials; and
(3) Salts and concentrates obtained by evaporating natural mineral waters.
4. Heading 30.06 applies only to the following, which are to be classified in that heading and in no other heading of the Nomenclature:
(a) Sterile surgical catgut, similar sterile suture materials (including sterile absorbable surgical or dental yarns) and sterile tissue adhesives for surgical wound closure;
(b) Sterile laminaria and sterile laminaria tents;
(c) Sterile absorbable surgical or dental haemostatics; sterile surgical or dental adhesion barriers, whether or not absorbable;
(d) Opacifying preparations for X-ray examinations and diagnostic reagents designed to be administered to the patient, being unmixed products put up in measured doses or products consisting of two or more ingredients which have been mixed together for such uses;
(e) Placebos and blinded (or double-blinded) clinical trial kits for use in recognised clinical trials, put up in measured doses, even if they might contain active medicaments;
(f) Dental cements and other dental fillings; bone reconstruction cements;
(g) First-aid boxes and kits;
(h) Chemical contraceptive preparations based on hormones, on other products of heading 29.37 or on spermicides;
(ij) Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments;
(k) Waste pharmaceuticals, that is, pharmaceutical products which are unfit for their original intended purpose due to, for example, expiry of shelf life; and
(l) Appliances identifiable for ostomy use, that is, colostomy, ileostomy and urostomy pouches cut to shape and their adhesive wafers or faceplates.
Subheading Notes
1. For the purposes of subheadings 3002.13 and 3002.14, the following are to be treated:
(a) As unmixed products, pure products, whether or not containing impurities;
(b) As products which have been mixed:
(1) The products mentioned in (a) above dissolved in water or in other solvents;
(2) The products mentioned in (a) and (b) (1) above with an added stabiliser necessary for their preservation or transport; and
(3) The products mentioned in (a), (b) (1) and (b) (2) above with any other additive.
2. Subheadings 3003.60 and 3004.60 cover medicaments containing artemisinin (INN) for oral ingestion combined with other pharmaceutical active ingredients, or containing any of the following active principles, whether or not combined with other pharmaceutical active ingredients: amodiaquine (INN); artelinic acid or its salts; artenimol (INN); artemotil (INN); artemether (INN); artesunate (INN); chloroquine (INN); dihydroartemisinin (INN); lumefantrine (INN); mefloquine (INN); piperaquine (INN); pyrimethamine (INN) or sulfadoxine (INN).
(*): Dạng uống là dạng sử dụng qua đường miệng (ví dụ, nuốt, nhai, ngậm, đặt dưới lưỡi…)
(SEN): Tham khảo Chú giải bổ sung (SEN) của Danh mục Thuế quan hài hòa ASEAN (AHTN) 2022